Logo for MindBio Therapeutics Corp.
MBIO
0.00%

MindBio Therapeutics Corp.

Status
ActiveT2
Issued & Outstanding142,957,291
Reserved for Issuance35,290,988
CurrencyCAD
CSE IndexNo

Quote

Last Price0.0250.00 (0.00%)
Volume4,000
Change0.00
Bid Size136,000
Bid Price0.02
Ask Price0.025
Ask Size172,000
Prev Close0.025
Open0.025
Day High0.025
Day Low0.025
52 Week High0.085
52 Week Low0.015

MindBio Therapeutics Corp.

Charts by TradingView

Depth Display

Recent Trades

About

MindBio Therapeutics Corp.

Listing Date
May 05, 2023

MindBio is a leading biotech/biopharma company focused on creating novel and emerging treatments for mental health conditions and is conducting world first take-home Microdosing (MB22001) human clinical trials.  MB22001 is MindBio’s lead candidate drug, a proprietary titratable form of Lysergic Acid Diethylamide (LSD) designed for take-home microdosing.  MindBio is a leader in microdosing of psychedelic medicines and is advancing its drug and technology protocols through clinical trials. MindBio has developed a multi-disciplinary platform for developing treatments and is involved in psychedelic medicine development and digital therapeutics, has completed Phase 1 clinical trials in 80 healthy participants, has a Phase 2a clinical trial just completed microdosing in patients with Major Depressive Disorder and a Phase 2B clinical trial currently underway microdosing in late stage cancer patients experiencing existential distress. The Company has also started dosing in a Phase 2B Depression Trial.   MindBio invests in research that forms the basis for developing novel and clinically proven treatments including digital technologies and interventions to treat debilitating health conditions such as depression, anxiety and other related mental health conditions.